IRIS
CASCINU, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.586
EU - Europa 6.166
AS - Asia 4.484
SA - Sud America 1.826
AF - Africa 266
Continente sconosciuto - Info sul continente non disponibili 13
OC - Oceania 4
Totale 25.345
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.465
SG - Singapore 1.557
BR - Brasile 1.528
UA - Ucraina 1.372
RU - Federazione Russa 751
IE - Irlanda 692
DE - Germania 668
CN - Cina 638
SE - Svezia 625
TR - Turchia 622
IT - Italia 602
VN - Vietnam 568
DK - Danimarca 541
HK - Hong Kong 483
FI - Finlandia 362
KR - Corea 279
GB - Regno Unito 200
FR - Francia 187
CI - Costa d'Avorio 123
AR - Argentina 114
IN - India 64
EC - Ecuador 63
ID - Indonesia 61
MA - Marocco 54
BD - Bangladesh 52
CA - Canada 48
MX - Messico 45
IQ - Iraq 42
ZA - Sudafrica 40
CO - Colombia 32
NL - Olanda 32
BE - Belgio 29
JP - Giappone 26
PL - Polonia 26
ES - Italia 22
PY - Paraguay 22
VE - Venezuela 20
CL - Cile 16
PE - Perù 16
PK - Pakistan 14
EG - Egitto 12
KE - Kenya 12
UY - Uruguay 12
AE - Emirati Arabi Uniti 11
EU - Europa 11
UZ - Uzbekistan 11
RO - Romania 10
DO - Repubblica Dominicana 8
DZ - Algeria 8
TN - Tunisia 8
AL - Albania 6
LT - Lituania 6
PH - Filippine 6
AT - Austria 5
BG - Bulgaria 5
KZ - Kazakistan 5
OM - Oman 5
SA - Arabia Saudita 5
CR - Costa Rica 4
CZ - Repubblica Ceca 4
HN - Honduras 4
IL - Israele 4
KG - Kirghizistan 4
MD - Moldavia 4
RS - Serbia 4
IR - Iran 3
LB - Libano 3
NP - Nepal 3
AU - Australia 2
AZ - Azerbaigian 2
BH - Bahrain 2
GY - Guiana 2
JM - Giamaica 2
KW - Kuwait 2
MY - Malesia 2
NG - Nigeria 2
PA - Panama 2
PS - Palestinian Territory 2
SI - Slovenia 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
CH - Svizzera 1
CY - Cipro 1
EE - Estonia 1
GD - Grenada 1
GE - Georgia 1
GR - Grecia 1
HU - Ungheria 1
IM - Isola di Man 1
JO - Giordania 1
KH - Cambogia 1
LV - Lettonia 1
LY - Libia 1
Totale 25.330
Salva come PNG Salva come JPEG
Città #
Dallas 1.911
Jacksonville 1.394
Ashburn 1.148
Fairfield 1.025
Singapore 870
Chandler 755
Dublin 692
Boardman 668
Wilmington 551
Hong Kong 479
Woodbridge 423
Houston 392
Seattle 371
New York 306
San Mateo 281
Lawrence 279
Princeton 279
Cambridge 272
The Dalles 237
Ann Arbor 220
Centro 205
Moscow 192
Ho Chi Minh City 190
Beijing 167
Des Moines 159
Los Angeles 154
Hefei 149
São Paulo 130
Hanoi 127
San Diego 123
Abidjan 122
Munich 73
Buffalo 62
Turin 48
London 47
Rio de Janeiro 46
Helsinki 44
Chicago 43
Turku 41
Brasília 35
Belo Horizonte 32
Porto Alegre 32
Milan 28
Haiphong 26
Santa Clara 26
Stockholm 26
Tokyo 25
Brussels 24
Curitiba 24
Montreal 24
Guayaquil 23
Warsaw 23
Chennai 22
Johannesburg 22
Marche 22
Norwalk 22
Orem 21
Biên Hòa 20
Kilburn 20
Brooklyn 19
Denver 19
Guangzhou 19
Campinas 18
Fortaleza 18
Quito 18
Frankfurt am Main 17
Ninh Bình 17
Rome 17
Baghdad 16
Guarulhos 16
Shanghai 16
Washington 16
Boston 15
Izmir 15
Da Nang 14
Dhaka 14
Hải Dương 14
Phoenix 14
Poplar 14
Pune 14
Can Tho 13
Manchester 13
San Francisco 13
Ankara 12
Atlanta 12
Bogotá 12
Thái Bình 12
Amsterdam 11
Buenos Aires 11
Columbus 11
Hounslow 11
Lima 11
Nairobi 11
Salt Lake City 11
Santo André 11
Ancona 10
Caruaru 10
Goiânia 10
Istanbul 10
Montevideo 10
Totale 15.737
Salva come PNG Salva come JPEG
Nome #
[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas 1.612
Anemia may influence the outcome of patients undergoing neoadjuvant treatment for rectal cancer 201
The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment 175
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: Molecular diagnostics and possible targets for personalized therapies 163
A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma. 157
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. 154
A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor. 154
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. 150
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: A multicentric retrospective analysis 150
Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in Renal Cell Carcinoma 149
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. 148
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients. 147
A cost-benefit analysis of chemotherapy for gastric cancer. 143
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. 143
KRAS: To be or not to be targeted? Biologic and computational analyses in pancreatic adenocarcinoma 141
Predictive and prognostic role of E-cadherin protein expression in patients with advanced gastric carcinomas treated with palliative chemotherapy. 140
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 140
Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. 139
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 136
A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer. 135
Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients. 134
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 133
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study 129
Neutrophil‑to‑lymphocyte ratio may be associated with the outcome in patients with prostate cancer 129
Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic target 127
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma patients 127
Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. 125
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management 124
Sub-cellular localization analysis of MSH6 missense mutations does not reveal an overt MSH6 nuclear transport impairment. 124
A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer. 122
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy 121
CANCER STEM CELL GENETIC PROFILE AS PREDICTOR OF RELAPSE IN RADICALLY RESECTED COLORECTAL CANCER 121
A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). 121
Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis. 120
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. 118
Angiogenetic pathway as a therapeutic target in renal cell carcinoma. 117
Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: Are all mutations equal? 117
A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. 116
Panitumumab for the treatment of metastatic colorectal cancer: A review 116
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. 115
Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients. 115
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis 115
Progress of molecular targeted therapies for advanced renal cell carcinoma. 115
New target therapies in advanced pancreatic cancer. 114
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib 114
Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. 114
c-erbB-2 and common prognostic factors in breast cancer patients. 113
Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). 112
Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR treatment in colorectal cancer patients 111
Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. 110
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. 110
Role of β4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab. 110
A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. 109
Translational challenges from the 2014 Gastrointestinal Cancers Symposium: Toward a true tailored therapy through effective research 109
Locoregional treatments of unresectable liver metastases from colorectal cancer. 108
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises 108
Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer 108
Cancer of pancreas. 107
A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer. 107
A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). 107
The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer 107
Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis 106
Trattamento del carcinoma del pancreas. Attualità e prospettive 105
Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. 105
Transient sunitinib resistance in gastrointestinal stromal tumors. 105
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. 104
Doses of capecitabine and oral vinorelbine are not relevant for efficacy in breast cancer patients: an analysis of dose intensity. 104
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma 103
Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors 103
A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). 102
Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer 102
Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). 100
The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) polymorphisms in the prediction of clinical outcome for advanced renal cell carcinoma patients receiving first-line sunitinib 100
A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer. 99
A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. 99
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 99
Recombinant human erythropoietin in chemotherapy-associated anemia. 98
Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. 97
The challenge of targeted therapies for gastric cancer patients: The beginning of a long journey 97
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. 97
Adjuvant chemotherapy in colon cancer: can we improve quality of care? 97
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management 97
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. 97
Pain and its treatment in hospitalized patients with metastatic cancer. 96
Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes. 96
Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. 95
5-Fluorouracil, leucovorin and interferon alpha 2b in advanced pancreatic cancer: a pilot study. 95
Escalating dose of tegafur combined with oral etoposide in metastatic gastric carcinoma. 94
Palliative treatment 94
A randomized, double blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel. 94
Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial. 93
Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. 93
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 93
Immunocytochemical evaluation of HER-2/neu on fine-needle aspirates from primary breast carcinomas. 92
Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: It is not about the destination, it is about the journey 92
Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs. 91
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? 91
Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer 90
Insulin-like Growth Factor (IGF) 1 and 2 help to predict disease outcome in GIST patients 89
Role of STAT3 pathway in genitourinary tumors 89
Totale 13.049
Salva come PNG Salva come JPEG
Categoria #
all - tutte 129.719
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 129.719
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.192 0 0 0 0 0 283 403 263 359 316 374 194
2021/20221.931 113 522 16 69 19 147 71 128 131 207 128 380
2022/20232.713 308 301 215 168 191 322 3 123 837 13 181 51
2023/20241.733 327 31 73 351 320 324 35 34 0 27 15 196
2024/20253.893 386 340 189 27 131 55 337 140 1.099 420 352 417
2025/20266.840 567 1.198 1.884 1.651 1.012 528 0 0 0 0 0 0
Totale 25.507